Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
KIMS
Dr. Bhaskara Rao Bollineni · Secunderabad, India
₹798.00
▬-0.04%KIMS (KIMS.NS) is trading with a strong BUY rating despite some elevated valuation metrics and high debt levels, driven by its strong revenue growth and dominant market position in the Indian healthcare sector.
Exchange
NSI
Currency
INR
Day range
₹792.10 – ₹804.90
52-week range
₹575.80 – ₹858.00
Sector
Healthcare
Industry
Medical Care Facilities
AI investment rating
AI analysis80% confidence
We consider the stock fairly valued relative to its 1-year range, but see room for growth considering its consistent revenue expansion and improving profitability.
7.0% below the 1-year high · trend down
Hedge-fund memo
Today
-0.04% decline due to profit taking in an otherwise strong uptrend.
This week
Trading near the top end of the 52-week range suggests some exhaustion of recent gains.
This month
We are cautious on the short-term outlook amid high valuations and rising interest rates.
Bull thesis
Bear thesis
Narrative read
Bullish
Composite sentiment
Institutional
Strong Buy
Retail
Buy
News flow
+10%
Read
We have factored in the recent decline in sentiment scores from the institutional and retail investors, which could be a buying opportunity.
Live news feed unavailable right now — showing the AI's qualitative read instead. Not scraped platform data.
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 0 of 4 recent quarters (EPS actual vs. consensus).
1.2242 vs 1.52833
-19.90% surprise
1.33 vs 1.38333
-3.86% surprise
1.67557 vs 2.24
-25.20% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| KIMS | 319.31B | 131.47 | 9.72% | 11.50% | 34.80% |
| VIJAYA | 140.10B | 81.25 | 19.70% | 32.45% | 26.60% |
| RAINBOW | 151.73B | 54.47 |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 500sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Regulatory Risks
Mitigation: The company has a strong track record of compliance with regulatory requirements and is likely to maintain its adherence to industry standards.
Business intelligence
Competitive moat
KIMS' strong brand recognition, extensive network of hospitals and medical facilities, and ability to offer quality healthcare services at scale provide a defendable competitive moat.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
Beat consensus earnings estimates
Thesis builder
Bull case
KIMS' strong revenue growth trajectory and improving profitability will continue to drive share price appreciation over the medium to long term.
Base case
The company will maintain its market position as a leading operator in the Indian healthcare sector.
Bear case
The high debt-to-equity ratio and elevated valuation metrics will lead to a decline in share price over the medium to long term.
Time horizon
2-3 years
Est. CAGR
20% – 25%
Entry (qual.)
Investors can consider entering the stock at present levels, given its strong fundamental and technical indicators.
Exit (qual.)
Investors may consider exiting the stock if the debt-to-equity ratio deteriorates or the hospital services sector witnesses a significant decline in demand.
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how KIMS fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain KIMS for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden risks
Hidden opportunities
Watch next
Investors with a 12-24 month time horizon may consider allocating to KIMS for its strong growth prospects and potential for market-beating returns.
Annual income statement, oldest → newest. Live via Yahoo.
1.96 vs 2.406
-18.54% surprise
| 17.94% |
| 22.56% |
| 24.30% |
| NH | 422.51B | 52.06 | 19.84% | 13.72% | 75.80% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹792.10
Resistance (day/52w high)
₹804.90
Volume
5,92,073
Trend
down
RSI (14)
39
MACD
bearish
MA cross
golden
50-day MA
₹790.74
200-day MA
₹698.76
vs 200-DMA
14.2%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.
Overall conviction 80%